Protara Therapeutics, Inc.
TARA
$3.97
-$0.07-1.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.88% | 15.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.88% | 29.26% | |||
| Operating Income | -2.88% | -29.26% | |||
| Income Before Tax | -2.74% | -30.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.74% | -30.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.74% | -30.54% | |||
| EBIT | -2.88% | -29.26% | |||
| EBITDA | -2.91% | -29.40% | |||
| EPS Basic | 17.80% | -19.87% | |||
| Normalized Basic EPS | 17.75% | -19.85% | |||
| EPS Diluted | 17.80% | -19.87% | |||
| Normalized Diluted EPS | 17.75% | -19.85% | |||
| Average Basic Shares Outstanding | 24.97% | 8.92% | |||
| Average Diluted Shares Outstanding | 24.97% | 8.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||